CPG
ADCT icon

Cornerstone Planning Group’s ADC Therapeutics ADCT Stock Holding History

Cornerstone Planning Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-276
Closed -$831 – 1402
2024
Q3 		$831 Buy
+276
New +$870 ﹤0.01% 976
2023
Q4 		– Sell
-14
Closed -$13 – 966
2023
Q3 		$13 Buy
+14
New +$19 ﹤0.01% 1185

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornerstone Planning Group's ADCT Position: Q4 2024 in Review

Cornerstone Planning Group sold out of ADC Therapeutics (ADCT) in Q4 2024, closing a stake of 276 shares — an estimated $831 sold.

Cornerstone Planning Group first reported a position in ADCT in Q3 2023 and held it in 2 quarters. The position peaked at $831 in Q3 2024. 83 funds tracked by Wall St. Rank hold ADCT as of Q4 2024.

  • Cornerstone Planning Group reported no remaining ADC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cornerstone Planning Group sold 276 ADC Therapeutics shares in Q4 2024, an estimated $831.
  • Cornerstone Planning Group first reported a position in ADC Therapeutics in Q3 2023 and held it in 2 quarters.
  • Cornerstone Planning Group's ADC Therapeutics position peaked at $831 in Q3 2024.
  • 83 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2024.

Based on Cornerstone Planning Group's 13F filing for Q4 2024, filed 29 Jan 2025.